This company has been marked as potentially delisted and may not be actively trading. Oasmia Pharmaceutical AB (publ) (OASM) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock OASM vs. ATNF, RNAZ, MBIO, IXHL, INDP, APM, CNSP, ENSC, CPHI, and QNRXShould you be buying Oasmia Pharmaceutical AB (publ) stock or one of its competitors? The main competitors of Oasmia Pharmaceutical AB (publ) include 180 Life Sciences (ATNF), TransCode Therapeutics (RNAZ), Mustang Bio (MBIO), Incannex Healthcare (IXHL), Indaptus Therapeutics (INDP), Aptorum Group (APM), CNS Pharmaceuticals (CNSP), Ensysce Biosciences (ENSC), China Pharma (CPHI), and Quoin Pharmaceuticals (QNRX). These companies are all part of the "medical" sector. Oasmia Pharmaceutical AB (publ) vs. 180 Life Sciences TransCode Therapeutics Mustang Bio Incannex Healthcare Indaptus Therapeutics Aptorum Group CNS Pharmaceuticals Ensysce Biosciences China Pharma Quoin Pharmaceuticals 180 Life Sciences (NASDAQ:ATNF) and Oasmia Pharmaceutical AB (publ) (NASDAQ:OASM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, community ranking, valuation, institutional ownership and profitability. Which has more risk & volatility, ATNF or OASM? 180 Life Sciences has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Comparatively, Oasmia Pharmaceutical AB (publ) has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Does the MarketBeat Community believe in ATNF or OASM? Oasmia Pharmaceutical AB (publ) received 124 more outperform votes than 180 Life Sciences when rated by MarketBeat users. Likewise, 65.97% of users gave Oasmia Pharmaceutical AB (publ) an outperform vote while only 15.38% of users gave 180 Life Sciences an outperform vote. CompanyUnderperformOutperform180 Life SciencesOutperform Votes215.38%Underperform Votes1184.62% Oasmia Pharmaceutical AB (publ)Outperform Votes12665.97% Underperform Votes6534.03% Does the media refer more to ATNF or OASM? In the previous week, 180 Life Sciences had 1 more articles in the media than Oasmia Pharmaceutical AB (publ). MarketBeat recorded 1 mentions for 180 Life Sciences and 0 mentions for Oasmia Pharmaceutical AB (publ). 180 Life Sciences' average media sentiment score of 1.89 beat Oasmia Pharmaceutical AB (publ)'s score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the media. Company Overall Sentiment 180 Life Sciences Very Positive Oasmia Pharmaceutical AB (publ) Neutral Do insiders and institutionals believe in ATNF or OASM? 4.1% of 180 Life Sciences shares are held by institutional investors. Comparatively, 0.1% of Oasmia Pharmaceutical AB (publ) shares are held by institutional investors. 0.2% of 180 Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is ATNF or OASM more profitable? 180 Life Sciences has a net margin of 0.00% compared to Oasmia Pharmaceutical AB (publ)'s net margin of -8,633.64%. Oasmia Pharmaceutical AB (publ)'s return on equity of -43.94% beat 180 Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A -558.93% -54.10% Oasmia Pharmaceutical AB (publ) -8,633.64%-43.94%-28.92% Which has stronger earnings & valuation, ATNF or OASM? Oasmia Pharmaceutical AB (publ) has higher revenue and earnings than 180 Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/A-$19.93MN/AN/AOasmia Pharmaceutical AB (publ)$220K6.82-$18.95MN/AN/A SummaryOasmia Pharmaceutical AB (publ) beats 180 Life Sciences on 7 of the 12 factors compared between the two stocks. Get Oasmia Pharmaceutical AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for OASM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OASM vs. The Competition Export to ExcelMetricOasmia Pharmaceutical AB (publ)Pharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.50M$6.86B$5.58B$8.61BDividend YieldN/A2.49%5.27%4.19%P/E RatioN/A8.8427.2920.07Price / Sales6.82257.85410.86158.91Price / CashN/A65.8538.2534.64Price / Book0.036.597.124.71Net Income-$18.95M$143.71M$3.23B$247.80M Oasmia Pharmaceutical AB (publ) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OASMOasmia Pharmaceutical AB (publ)N/A$0.02flatN/AN/A$1.50M$220,000.000.0057ATNF180 Life SciencesN/A$1.04-1.9%N/A-32.0%$5.92MN/A0.007Gap UpRNAZTransCode Therapeutics2.8371 of 5 stars$7.03-0.8%$280.00+3,882.9%-100.0%$5.86MN/A0.009MBIOMustang Bio1.1824 of 5 stars$1.29-1.5%N/A-81.3%$5.65MN/A-0.02100Positive NewsShort Interest ↑Gap DownIXHLIncannex Healthcare0.557 of 5 stars$0.19-4.7%N/A-93.7%$5.60M$98,000.00-0.143Short Interest ↓Gap DownINDPIndaptus Therapeutics3.9342 of 5 stars$0.35+2.1%$8.50+2,344.6%-86.5%$5.58MN/A-0.206Short Interest ↑Gap DownAPMAptorum Group2.1946 of 5 stars$1.04+3.5%N/A-76.2%$5.53M$430,000.000.0030Positive NewsGap UpCNSPCNS Pharmaceuticals1.2541 of 5 stars$1.01+1.0%$25.00+2,375.2%-99.5%$5.52MN/A-0.015Positive NewsShort Interest ↓ENSCEnsysce Biosciences0.0963 of 5 stars$2.30+3.6%N/A-76.1%$5.45M$2.23M-0.0810Short Interest ↓CPHIChina Pharma0.1307 of 5 stars$1.63-3.0%N/A-94.0%$5.32M$4.30M0.00250News CoverageShort Interest ↓QNRXQuoin Pharmaceuticals0.633 of 5 stars$8.91+1.9%N/A-68.5%$5.24MN/A-2.204Short Interest ↓ Related Companies and Tools Related Companies ATNF Competitors RNAZ Competitors MBIO Competitors IXHL Competitors INDP Competitors APM Competitors CNSP Competitors ENSC Competitors CPHI Competitors QNRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OASM) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oasmia Pharmaceutical AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Oasmia Pharmaceutical AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OASM Stock Free OASM Stock Alerts